.jpeg){kind=spacer}
The Medical Technology Association of India (MTaI) has strong objections to a recent notification issued by the Maharashtra Medical Council (MMC) that allows homoeopathy practitioners to administer allopathic drugs
India's pharmaceutical sector is undergoing a significant transformation, both in the discovery of new medicines and advancements in drug delivery.
VarmX, a Dutch-based biotech company headquartered in Leiden, has been given clearance by the U. S. FDA to carry out a pivotal Phase 3 clinical trial on its lead candidate, the VMX-C001. The novel bypass agent can be used to reactivate coagulati...
Aster DM Healthcare has established its objective to become India’s largest hospital chain, implementing an aggressive expansion plan in Tier-2 cities like Indore, Raipur, Aurangabad and Bhubaneswar...
WIKA Instruments India, the world's leading precision measurement solution provider, has introduced its newest strategic movement titled 'Re-Inventing Hygiene' to revolutionize the standard of hygiene in the pharmaceutical sector.
Emcure Pharmaceuticals has incorporated a new wholly-owned subsidiary, Emcure Wellness Private Limited, indicating a strategic direction towards diversifying within India's growing healthcare and wellness sector. The new subsidiary was formed on...
A substantial milestone in the therapeutic market of advanced prostate cancer, RedHill Biopharma Ltd. has launched the patient enrollment in a larger Phase 2 study focusing on metastatic castrate-resistant prostate cancer (mCRPC). The project indicat
In an aim to expand in the high-value complex generics, Indian pharma major Lupin has introduced Ipratropium Bromide Nasal Solution to the United States. The product is the 0.03 percent and 0.06 percent generic equivalent of Atrovent Nasal Spray, whi
Biosimilar market in India is poised to boom in 2025, due to increasing rates of chronic diseases, patent expiration, and also a favorable policy environment. Within the domestic revenue, the biosimilars portion grew from roughly USD 866 million
In a Phase III research of ART-123, Asahi Kasei Pharma has begun trial drug administration in Japan to avoid symptoms associated with chemotherapy-induced peripheral neuropathy. This statement comes after positive results from previous Phase I and II
.jpg)
, CDSCO.jpg)